You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Transformed indolent Lymphoma

Showing 1 - 25 of 5,564
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • (no location specified)
Jun 28, 2023

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Chronic Lymphocytic Leukemia, DLBCL, Follicular Lymphoma Trial in Duarte, Boston, Portland (Copanlisib, Nivolumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Duarte, California
  • +2 more
Mar 9, 2022

Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma Trial in Miami, Baltimore, Milwaukee (Zydelig)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +8 more
  • Miami, Florida
  • +2 more
Apr 21, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • +8 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 8, 2023

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

Active, not recruiting
  • Aggressive Non-Hodgkin Lymphoma
  • +13 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 18, 2022

Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2

Active, not recruiting
  • Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • External Beam Radiation Therapy
  • Orbital Radiation
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Mantle Cell Lymphoma Trial (Zanubrutinib, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
Nov 22, 2022

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Terminated
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 24, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
Has Results
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Hematopoietic Cell Transplantation Recipient, Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma Trial in Columbus

Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +11 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 29, 2021

Indolent Lymphoma, Low-dose Radiotherapy Trial in Beijing (Low-dose radiotherapy)

Recruiting
  • Indolent Lymphoma
  • Low-dose Radiotherapy
  • Low-dose radiotherapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Sep 13, 2022

Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of

Active, not recruiting
  • Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
  • Copanlisib (BAY80-6946)
  • Multiple Locations, Taiwan
    Many Locations
Jan 31, 2023

Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic

Not yet recruiting
  • Recurrent Transformed Chronic Lymphocytic Leukemia
  • +7 more
  • Biospecimen Collection
  • +9 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 15, 2023

Lymphoma Trial in Houston (Ibritumomab Tiuxetan (Zevalin), Rituximab)

Completed
Has Results
  • Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Aug 30, 2022

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Trial in Milano (intralesional rituximab, supplemental autologous

Completed
  • Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
  • intralesional rituximab
  • supplemental autologous serum
  • Milano, Italy
    Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
Aug 2, 2022

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
Nov 17, 2022

Severe COVID-19 Infection in CLL or B-NHL Who Received

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
    • (no location specified)
    Apr 6, 2023